Following surgical resection of Dukes' B or C colorectal cancers 72 patients have been randomly allocated to receive : 5-fluorouracil; or 5-fluorouracil and levamisole; or no treatment. Adjuvant treatment was continued for one year. 66 patients remain evaluable for up to 24 months. Preliminary results show no significant differences in survival or recurrence rates. Two patients receiving 5-fluorouracil and levamisole developed severe, but reversible, neutropenia. Other side effects were uncommon.
Introduction
Despite intensive investigation the results of treatment for colorectal cancer remain poor and have changed little in the last three decades. Surgical resection is still the only potentially curative form of treatment for most cases, although radiotherapy may have a place in the . management of early rectal cancer (Gerard 1978 , Papilion 1974 . Chemotherapy and immunotherapy offer no prospect of cure when used alone. Recently, interest has been attracted by the suggestion that cancer treatment may be improved by the use of chemotherapy or immunotherapy after apparently successful surgical resection. This approach may be of some benefit in breast cancer (Fisher et 01. 1977 , Bonadonna et 01. 1977 and possibly also in stomach cancer (Imanaga & Nakazato 1977 , Nakajima et 01. 1978 and lung cancer (McKneally et 01. 1977 , Jansen et 01. 1978 , although results are at a preliminary stage.
We have undertaken a randomized trial of chemotherapy and immunotherapy with 5fluorouracil (5-FU) and levamisole following resection of colorectal cancers. Preliminary results are reported.
Methods
Patients aged 75 years or less following surgical resection of Dukes' B or C colorectallesions were randomly allocated to one of the following treatment groups: no adjuvant treatment; 5-FU; 5-FU and levamisole. Treatment was started four to eight weeks after surgery and continued for 12 months. Allocation to the treatment groups was done by the participating clinician by opening a sealed envelope. Patients were followed up monthly for one year, then at 15,18 and 24 months, and annually thereafter. At each visit blood was removed for routine haematology and biochemistry, including liver function tests. A barium enema was done at one year. Isotope liver scans and ultrasonography were done at the clinician's discretion. CEA estimation was not available to all clinicians and was not done routinely.
5-FU (12 mg per kg body weight) was given orally in milk for five consecutive days every four weeks; treatment was continued for 12 cycles subject to haematological control. Levamisole (200 mg daily in divided doses) was given orally for two consecutive days per week during the three rest weeks from chemotherapy. Results 72 patients have so far entered the trial. 52 patients have been followed up for at least 6 months and 22 for 24 months. Six patients have been withdrawn from the trial for various protocol violations. The results are shown in Table 1 . Only patients followed up for more than six months are included. Although allocation to the three treatment groups is even, there is at present an uneven distribution of Dukes' Band C cases between the three groups.
The results are very preliminary, but have been scrutinized by an independent statistician and show no significant trend so far.
Serious side effects were uncommon. Two patients in the 5-FU and levamisole group developed severe neutropenia. Both recovered when treatment was stopped. 5-FU alone was later given to both patients without ill effect. Most patients had mild nausea at the start of treatment, but this appeared to diminish quickly with successive courses. Antiemetics were rarely required. One patient developed a troublesome arthralagia which improved when levamisole was stopped.
Discussion
Recent attempts to improve the prognosis of colorectal cancer have involved the use of preoperative radiotherapy (Roswit et al. 1975 ,Steams et al. 1974 (Table 2) . None showed significant improvement of survival, although Grage et al. (I 977) reported an increase in the disease-free interval in patients with Dukes' C carcinoma. It is unlikely that these results will be improved by present multiple-agent chemotherapy. It had been suggested by Moertel et al. (1975) that combination treatment with methyl-CCNU, 5-FU and vincristine was superior to 5·FU alone for advanced colorectal disease. However, the initial high response rates have not been confirmed by subsequent studies (Abdallah et al. 1977 , Moertel1978, Engstrom et al. 1978 ,and no better combination has been found. Several trials of adjuvant treatment with combination chemotherapy (methyl-CCNU and 5-rU) are, however, in progress in the United States. In theory, at least, immunotherapy is an attractive form of treatment. Non-randomized trials of levamisole in the treatment of colorectal cancer (Verhaegen 1980)and gastric cancer (Miwa & Orita 1978) following resection have suggested some improvement in survival, but information from properly randomized trials is lacking. Combined treatment with both chemotherapy and immunotherapy may be of some benefit by combining two relatively weak forms of systemic treatment with different actions. This was the rationale in the present study.
Although numbers are small no benefit is apparent as yet from the use of chemotherapy and immunotherapy in this study.
A number of other workers have reported a high incidence of side effects with levamisole. Parkinson et al. (I 977) had to discontinue the drug in 21.7% of patients because of intolerable but reversible side effects -principally gastrointestinal upsets and a 'flu-like' syndrome. None of our patients developed these complications. Reversible granulocytopenia was seen in two cases from our series. This appeared after the first cycle of treatment in one patient, and after the second in the other. The blood picture returned to normal in both patients when the treatment was stopped. Both patients subsequently received 5-FU without incident. This is in line with previous experience in breast cancer patients (Teerenhovi et al. 1978 , Retsas et al. 1978 . A study in lung cancer patients (Anthony et al. 1979 ) showed significantly poorer survival in the treatment group. This was due to an excess of cardiorespiratory deaths in the four.to six weeks after operation. No such effect has been seen in our own small series, possibly because treatment was not started less than six weeks postoperatively.
It has been suggested by Higgins (I978) that benefit from adjuvant chemotherapy is eventually seen in the patients who have survived for at least two years. This may be because patients with extensive disseminated disease die irrespective of treatment, whereas patients with a small tumour load do respond to treatment. Since a similar effect may become apparent in the present study it is proposed to continue entry to the trial.
